BSE Live
Apr 02, 16:01Prev. Close
5.23
Open Price
5.79
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of DECIPHER LABS (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 0.17 | 0.47 | 0.23 | -0.23 | -1.60 | |
| Diluted EPS (Rs.) | 0.17 | 0.47 | 0.23 | -0.23 | -1.60 | |
| Cash EPS (Rs.) | 0.17 | 0.47 | 0.23 | -0.23 | -1.49 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 10.96 | 3.12 | 2.65 | 2.42 | 2.65 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 10.96 | 3.12 | 2.65 | 2.42 | 2.65 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 1.41 | 8.48 | 1.27 | 0.47 | 0.28 | |
| PBDIT/Share (Rs.) | 0.17 | 0.47 | 0.23 | -0.23 | -1.49 | |
| PBIT/Share (Rs.) | 0.17 | 0.47 | 0.23 | -0.23 | -1.60 | |
| PBT/Share (Rs.) | 0.17 | 0.47 | 0.23 | -0.23 | -1.60 | |
| Net Profit/Share (Rs.) | 0.17 | 0.47 | 0.23 | -0.23 | -1.60 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 12.01 | 5.56 | 17.94 | -49.17 | -534.64 | |
| PBIT Margin (%) | 11.76 | 5.55 | 17.94 | -49.17 | -573.03 | |
| PBT Margin (%) | 11.76 | 5.55 | 17.94 | -49.17 | -573.03 | |
| Net Profit Margin (%) | 11.80 | 5.55 | 17.94 | -49.17 | -573.03 | |
| Return on Networth / Equity (%) | 1.51 | 15.09 | 8.60 | -9.51 | -60.21 | |
| Return on Capital Employed (%) | 1.51 | 15.09 | 8.60 | -9.28 | -60.21 | |
| Return on Assets (%) | 1.44 | 6.45 | 6.15 | -7.16 | -49.00 | |
| Total Debt/Equity (X) | 0.02 | 0.06 | 0.06 | 0.02 | 0.00 | |
| Asset Turnover Ratio (%) | 12.22 | 1.54 | 34.31 | 14.57 | 8.55 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 5.36 | 1.73 | 3.51 | 0.60 | 0.81 | |
| Quick Ratio (X) | 4.81 | 1.63 | 3.40 | 0.48 | 0.37 | |
| Inventory Turnover Ratio (X) | 4.47 | 29.36 | 10.45 | 5.33 | 1.06 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 19.24 | 20.12 | 16.27 | 6.57 | 4.85 | |
| EV/Net Operating Revenue (X) | 13.52 | 2.97 | 16.01 | 17.53 | 21.73 | |
| EV/EBITDA (X) | 112.51 | 53.29 | 89.20 | -35.65 | -4.06 | |
| MarketCap/Net Operating Revenue (X) | 13.37 | 2.95 | 15.90 | 17.49 | 21.74 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 1.72 | 8.01 | 7.62 | 3.39 | 2.29 | |
| Price/Net Operating Revenue | 13.38 | 2.95 | 15.91 | 17.52 | 21.80 | |
| Earnings Yield | 0.01 | 0.02 | 0.01 | -0.03 | -0.26 |
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth